[2-(11,17-dihydroxy-10,13-dimethyl-3-oxo-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-17-yl)-2-oxo-ethyl] 4-[4-[bis(2-chloroethyl)amino]phenyl]butanoate

Names

[ Name ]:
[2-(11,17-dihydroxy-10,13-dimethyl-3-oxo-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-17-yl)-2-oxo-ethyl] 4-[4-[bis(2-chloroethyl)amino]phenyl]butanoate

[Synonym ]:
precorrin-6y
3,7,12,17-Corrintetrapropanoic acid,2,8,13,18-tetrakis(carboxymethyl)-7,8,11,12-tetradehydro-9,10,11,22-tetrahydro-3,9,13,18,19-pentamethyl-,(1R-(1alpha,2alpha,3beta,9beta,13alpha,17beta,18alpha,19beta))

Biological Activity

[Description]:

Prednimustine (Leo 1031;NSC 134087) is the ester formed from Prednisolone (HY-17463) and Chlorambucil (HY-13593). Prednimustine can be used for leukemias and lymphomas research[1].

[Related Catalog]:

Research Areas >> Cancer

Signaling Pathways >> Cell Cycle/DNA Damage >> DNA Alkylator/Crosslinker

[In Vivo]

Prednimustine (120 mg/kg; s.c.; single dose) shows much less toxic than equimolar doses of Chlorambucil (HY-13593) (60 mg/kg; s.c.; single dose) in non-tumour-bearing rat model, due to differences in alkylating agent pharmacokinetics[1]. Prednimustine (40 mg/kg; s.c.; single dose) produces low plasma concentrations (less than 5 microM) of the alkylating metabolites chlorambucil and phenyl acetic mustard, which were maintained for 48 h in rats bearing the sensitive strain of the Walker 256 carcinosarcoma grown as an ascites[1]. Prednimustine (40 mg/kg;s.c.; single dose; measured at 72 h) shows antitumor effect in rats model with the alkylating agent-resistant strain of the Yoshida sarcoma[1]. Animal Model: Female Wistar rats non-tumour-bearing (150-200g)[1] Dosage: 120 mg/kg Administration: Subcutaneous injection; single dose; observed at day 21 Result: Remained 100% survival of rats, while 0% survival for Chlorambucil treatment group. Animal Model: Female Wistar rats bearing the alkylating agent-resistant strain of the Yoshida sarcoma (150-200g)[1] Dosage: 40 mg/kg Administration: Subcutaneous injection; single dose Result: Killed 57% of the resistant tumour cells.

Chemical & Physical Properties

[ Density]:
1.3g/cm3

[ Boiling Point ]:
791.5ºC at 760 mmHg

[ Melting Point ]:
163-164ºC

[ Molecular Formula ]:
C₃₅H₄₅Cl₂NO₆

[ Molecular Weight ]:
646.64100

[ Flash Point ]:
432.5ºC

[ Exact Mass ]:
645.26200

[ PSA ]:
104.14000

[ LogP ]:
5.41540

[ Vapour Pressure ]:
2.08E-26mmHg at 25°C

[ Index of Refraction ]:
1.606

Toxicological Information

CHEMICAL IDENTIFICATION

RTECS NUMBER :: TU4153000

CHEMICAL NAME :: Pregna-1,4-diene-3,20-dione, 11-beta,17,21-trihydroxy-, 21-(4-(p-(bis(2-chloroethyl)amino) phenyl)butyrate)

CAS REGISTRY NUMBER :: 29069-24-7

LAST UPDATED :: 199612

DATA ITEMS CITED :: 7

MOLECULAR FORMULA :: C35-H45-Cl2-N-O6

MOLECULAR WEIGHT :: 646.71

WISWESSER LINE NOTATION :: L E5 B666 OV AHTTT&J A1 CQ E1 FV1OV3R DN2G2G& FQ

HEALTH HAZARD DATA

ACUTE TOXICITY DATA

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Human

DOSE/DURATION :: 16 mg/kg/4W

TOXIC EFFECTS :: Behavioral - euphoria Blood - leukopenia Blood - thrombocytopenia

REFERENCE :: JNMDBO Journal of Medicine (Westbury, NY). (PJD Pub., Ltd., POB 966, Westbury, NY 11590) V.1- 1970- Volume(issue)/page/year: 8,115,1977

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: 530 mg/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

REFERENCE :: DRFUD4 Drugs of the Future. (J.R. Prous, S.A., Apartado de Correos 540, 08080 Barcelona, Spain) V.1- 1975/76- Volume(issue)/page/year: 1,137,1976

TYPE OF TEST :: LDLo - Lowest published lethal dose

ROUTE OF EXPOSURE :: Subcutaneous

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: 128 mg/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

REFERENCE :: EJCAAH European Journal of Cancer. (Oxford, UK) V.1-17(6), 1965-1981. For publisher information, see EJCODS. Volume(issue)/page/year: 13,873,1977

TYPE OF TEST :: LDLo - Lowest published lethal dose

ROUTE OF EXPOSURE :: Subcutaneous

SPECIES OBSERVED :: Rodent - mouse

DOSE/DURATION :: 128 mg/kg

TOXIC EFFECTS :: Tumorigenic - active as anti-cancer agent

REFERENCE :: EJCAAH European Journal of Cancer. (Oxford, UK) V.1-17(6), 1965-1981. For publisher information, see EJCODS. Volume(issue)/page/year: 13,873,1977 *** REVIEWS *** IARC Cancer Review:Animal Inadequate Evidence IMEMDT IARC Monographs on the Evaluation of Carcinogenic Risk of Chemicals to Man. (WHO Publications Centre USA, 49 Sheridan Ave., Albany, NY 12210) V.1- 1972- Volume(issue)/page/year: 50,115,1990 IARC Cancer Review:Human No Adequate Data IMEMDT IARC Monographs on the Evaluation of Carcinogenic Risk of Chemicals to Man. (WHO Publications Centre USA, 49 Sheridan Ave., Albany, NY 12210) V.1- 1972- Volume(issue)/page/year: 50,115,1990 IARC Cancer Review:Group 3 IMEMDT IARC Monographs on the Evaluation of Carcinogenic Risk of Chemicals to Man. (WHO Publications Centre USA, 49 Sheridan Ave., Albany, NY 12210) V.1- 1972- Volume(issue)/page/year: 50,115,1990

Related Compounds

The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.